Continuous ultrafiltration for congestive heart failure: the CUORE trial

J Card Fail. 2014 Jan;20(1):9-17. doi: 10.1016/j.cardfail.2013.11.004. Epub 2013 Nov 20.

Abstract

Background: There are limited data comparing ultrafiltration with standard medical therapy as first-line treatment in patients with severe congestive heart failure (HF). We compared ultrafiltration and conventional therapy in patients hospitalized for HF and overt fluid overload.

Methods and results: Fifty-six patients with congestive HF were randomized to receive standard medical therapy (control group; n = 29) or ultrafiltration (ultrafiltration group; n = 27). The primary end point of the study was rehospitalizations for congestive HF during a 1-year follow-up. Despite similar body weight reduction at hospital discharge in the 2 groups (7.5 ± 5.5 and 7.9 ± 9.0 kg, respectively; P = .75), a lower incidence of rehospitalizations for HF was observed in the ultrafiltration-treated patients during the following year (hazard ratio 0.14, 95% confidence interval 0.04-0.48; P = .002). Ultrafiltration-induced benefit was associated with a more stable renal function, unchanged furosemide dose, and lower B-type natriuretic peptide levels. At 1 year, 7 deaths (30%) occurred in the ultrafiltration group and 11 (44%) in the control group (P = .33).

Conclusions: In HF patients with severe fluid overload, first-line treatment with ultrafiltration is associated with a prolonged clinical stabilization and a greater freedom from rehospitalization for congestive HF.

Trial registration: ClinicalTrials.gov NCT00360958.

Keywords: Congestion; diuretics; heart failure; ultrafiltration.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Body Weight / drug effects
  • Cardiovascular Agents / administration & dosage*
  • Confidence Intervals
  • Diuretics / administration & dosage
  • Dose-Response Relationship, Drug
  • Female
  • Furosemide / administration & dosage*
  • Heart Failure* / blood
  • Heart Failure* / diagnosis
  • Heart Failure* / mortality
  • Heart Failure* / physiopathology
  • Heart Failure* / therapy
  • Humans
  • Kidney Function Tests
  • Male
  • Monitoring, Physiologic / methods
  • Natriuretic Peptide, Brain / blood
  • Patient Readmission / statistics & numerical data
  • Proportional Hazards Models
  • Severity of Illness Index
  • Treatment Outcome
  • Ultrafiltration / methods*

Substances

  • Cardiovascular Agents
  • Diuretics
  • Natriuretic Peptide, Brain
  • Furosemide

Associated data

  • ClinicalTrials.gov/NCT00360958